Dachengqi Decoction for Enhancing Early Gastrointestinal Recovery After Whipple Surgery (NCT06948474) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Dachengqi Decoction for Enhancing Early Gastrointestinal Recovery After Whipple Surgery
China45 participantsStarted 2024-08-01
Plain-language summary
To investigate the clinical efficacy of the traditional Chinese medicine formula Dachengqi Decoction in promoting early gastrointestinal function recovery after Whipple surgery, and to evaluate its impact on postoperative nutritional status, hospitalization duration, and complication rates, thereby providing evidence for optimizing postoperative rehabilitation strategies in pancreaticoduodenectomy patients.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients aged 18-75 years, regardless of gender (n=45);
* Meeting American Society of Anesthesiologists (ASA) physical status classification I-II criteria, scheduled to undergo pancreaticoduodenectomy or pylorus-preserving pancreaticoduodenectomy under combined intravenous-inhalational general anesthesia;
* No participation in other clinical trials within 6 months prior to the study initiation;
* Absence of severe preexisting cardiac, neurological, renal, endocrine, or hematologic diseases that may affect surgical outcomes or postoperative prognosis (e.g., unstable angina, heart failure, uncontrolled hypertension, severe neuropathy, psychiatric disorders, renal insufficiency, diabetes, hematologic disorders, severe alcoholic liver disease, substance abuse, or alcoholism);
* Participants free of cognitive impairment, aphasia, or psychiatric disorders, possessing intact communication skills and capable of comprehending and signing the informed consent form.
Exclusion Criteria:
* Patients aged \<18 or \>75 years;
* Not meeting American Society of Anesthesiologists (ASA) physical status classification I-II criteria;
* History of severe cardiac, neurological, renal, endocrine, or hematopoietic comorbidities that may impact surgical outcomes or postoperative prognosis (e.g., unstable angina, heart failure, uncontrolled hypertension, severe neuropathy, psychiatric disorders, renal insufficiency, diabetes, hematologic diseases, severe alcoholic liver disease,…
What they're measuring
1
One month postoperative evaluation of gastrointestinal function